What question did this study set out to answer?

Assess the efficacy, acceptability, tolerability, and safety of orexin receptor antagonists in major depressive disorder.

April 10, 2026Molecular PsychiatryOpen Access

Orexin receptor antagonists for major depressive disorder: perspectives from a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Assess the efficacy, acceptability, tolerability, and safety of orexin receptor antagonists in major depressive disorder.
Conducted a systematic review and meta-analysis based on DBRPCTs
Analyzed data from studies published before October 2025
Compiled outcomes using HDRS17 and MADRS scales
Seltorexant improved symptoms in major depressive disorder individuals
Other orexin receptor antagonists showed limited therapeutic benefit
Meta-analysis provided insights on acceptability and tolerability of QXR-ANTs

No takes yet. Share an insight, caveat, or question.

Systematic review and meta-analysis evaluate orexin receptor antagonists' efficacy in major depressive disorder, suggesting varied results.

Kishi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review and meta-analysis evaluate orexin receptor antagonists' efficacy in major depressive disorder, suggesting varied results.